Brian T. Powl's most recent trade in Kura Oncology Inc was a trade of 1,583 Common Stock done at an average price of $7.9 . Disclosure was reported to the exchange on Jan. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.87 per share. | 28 Jan 2025 | 1,583 | 59,667 (0%) | 0% | 7.9 | 12,461 | Common Stock |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 92,500 | 92,500 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 46,250 | 61,250 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 30,000 | 30,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Brian T. Powl | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 4.87 per share. | 05 Jul 2023 | 3,854 | 41,146 (0%) | 0% | 4.9 | 18,769 | Common Stock |
| Fate Therapeutics Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 425,000 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 45,000 | 45,000 (0%) | 0% | 0 | Common Stock |